This course will introduce basic concepts of pharmacovigilance, health outcomes, and health economics (pharmacoeconomics). Health Economics and Outcomes Research (HEOR) is becoming increasingly critical in the pharmacy profession. This is partly due to the healthcare system cost constraints and the increasing number of new and often expensive therapies coming to market; thus, additional evidence, beyond clinical trial data, is required to demonstrate the value of a therapy and its potential in clinical practice. To ensure successful reimbursement (i.e. funding) and subsequent uptake of a therapy, it is critical to generate and communicate evidence that demonstrates the added value of a therapy compared with available alternatives to relevant stakeholders, such as payers and healthcare professionals. Students will have the opportunity to evaluate the three components of HEOR (economic, humanistic, and clinical) and understand how these components are used in healthcare decision-making and clinical application. Students will learn to critically evaluate the pharmacoeconomic (PEC) /health outcomes literature and to assess/communicate the risks/benefits of marketed drugs through the introduction of pharmacovigilance. (PHAR 421)
PharmD